Aortic stenosis and lipids: Does intervention work?

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 379-384

  Wierzbicki, Anthony S ^a   Viljoen, Adie ^b   Chambers, John B ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

aortic stenosis; apolipoproteins; atherosclerosis; lipids; statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; ROSUVASTATIN;

AORTA ATHEROSCLEROSIS; AORTA STENOSIS; ATHEROSCLEROSIS; CALCIFICATION; CLINICAL TRIAL; DISEASE COURSE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; AORTIC VALVE STENOSIS; AZETIDINES; BIOMARKERS, PHARMACOLOGICAL; CALCINOSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; SIMVASTATIN; STRESS, PHYSIOLOGICAL;

EID: 77953812536     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283393c9b     Document Type: Review

References (68)

1. Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968; 38 (1 Suppl):61-67.
2. Chizner MA, Pearle DL, DeLeon AC Jr. The natural history of aortic stenosis in adults. Am Heart J 1980; 99:419-424.
3. Iivanainen AM, Lindroos M, Tilvis R, et al. Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol 1996; 78:97-101.
4. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J 1988; 9 (Suppl E):57-64.
5. Keller C, Schmitz H, Theisen K, et al. Regression of valvular aortic stenosis due to homozygous familial hypercholesterolemia following plasmapheresis. Klin Wochenschr 1986; 64:338-341.
6. Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin Vasc Med 2004; 4:43-50.
7. Lindroos M, Kupari M, Heikkila J, et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21:1220-1225.
8. Vandeplas A, Willems JL, Piessens J, et al. Frequency of angina pectoris and coronary artery disease in severe isolated valvular aortic stenosis. Am J Cardiol 1988; 62:117-120.
9. Kaden JJ, Eckert JP, Poerner T, et al. Prevalence of atherosclerosis of the coronary and extracranial cerebral arteries in patients undergoing aortic valve replacement for calcified stenosis. J Heart Valve Dis 2006; 15:165-168.
10. Hoagland PM, Cook EF, Flatley M, et al. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol 1985; 55:744-747.
11. Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001; 88:693-695. (Pubitemid 32831111)
12. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59:998-999. (Pubitemid 17074253)
13. Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76:928-932.
14. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006; 47:2229-2236.
15. Katz R, Budoff MJ, Takasu J, et al. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi- Ethnic Study of Atherosclerosis (MESA). Diabetes 2009; 58:813-819.
16. Lindroos M, Kupari M, Valvanne J, et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994; 15:865-870.
17. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29:630-634.
18. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 2007; 50:1992-1998.
19. Tunick PA, Freedberg RS, Kronzon I. Cardiac findings in the very elderly: analysis of echocardiography in fifty-eight nonagenarians. Gerontology 1990; 36:206-211.
20. O'Brien KD. Epidemiology and genetics of calcific aortic valve disease. J Investig Med 2007; 55:284-291.
21. Rashidi A, Adler DS, Casscells W, et al. Is it time to prescribe statins to patients with calcified aortic stenosis? Am Heart J 2005; 150:41-45.
22. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90:844-853.
23. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16:523-532.
24. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006; 26:1721-1728.
25. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24:1161-1170.
26. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification: basic science to clinical practice. Heart 2009; 95:616-623.
27. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995; 92:2163-2168.
28. Lehmann S, Walther T, Kempfert J, et al. Mechanical strain and the aortic valve: influence on fibroblasts, extracellular matrix, and potential stenosis. Ann Thorac Surg 2009; 88:1476-1483.
29. Ix JH, Chertow GM, Shlipak MG, et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115:2533-2539.
30. Rajamannan NM. Mechanisms of aortic valve calcification: the LDL-densityradius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 2010; 298:H5-15.
31. Skowasch D, Steinmetz M, Nickenig G, et al. Is the degeneration of aortic valve bioprostheses similar to that of native aortic valves? Insights into valvular pathology. Expert Rev Med Devices 2006; 3:453-462.
32. Yeghiazaryan K, Bauriedel G, Schild HH, et al. Prediction of degeneration of native and bioprosthetic aortic valves: issue-related particularities of diabetes mellitus. Infect Disord Drug Targets 2008; 8:88-99.
33. Kiani AN, Fishman EK, Petri M. Aortic valve calcification in systemic lupus erythematosus. Lupus 2006; 15:873-876. (Pubitemid 46044919)
34. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
35. Wierzbicki AS, Poston R, Ferro A. The lipid and nonlipid effects of statins. Pharmacol Ther 2003; 99:95-112.
36. Osman L, Chester AH, Amrani M, et al. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation 2006; 114 (1 Suppl):I566-I572.
37. Toli K, Paraskevas KI, Poulakou MV, et al. Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment? Expert Opin Ther Targets 2008; 12:1209-1215.
38. Toutouzas K, Drakopoulou M, Synetos A, et al. In vivo aortic valve thermal heterogeneity in patients with nonrheumatic aortic valve stenosis the: first in vivo experience in humans. J Am Coll Cardiol 2008; 52:758-763.
39. Skowasch D, Tuleta I, Steinmetz M, et al. Pathogen burden in degenerative aortic valves is associated with inflammatory and immune reactions. J Heart Valve Dis 2009; 18:411-417.
40. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004; 13:560-566.
41. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004; 36:57-66.
42. Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med 2006; 259:381-392.
43. Harrison DG, Widder J, Grumbach I, et al. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 2006; 259:351-363.
44. Butcher JT, Simmons CA, Warnock JN. Mechanobiology of the aortic heart valve. J Heart Valve Dis 2008; 17:62-73.
45. Baghdasarian SB, Jneid H, Hoogwerf BJ. Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther 2004; 26:337-351.
46. Wierzbicki A, Shetty C. Aortic stenosis: an atherosclerotic disease? J Heart Valve Dis 1999; 8:416-423.
47. Colli A, Gherli T, Mestres CA, et al. Degeneration of native and tissue prosthetic valve in aortic position: do statins play an effective role in prevention? Int J Cardiol 2007; 116:144-152.
48. Rossebo AB, Pedersen TR. Hyperlipidaemia and aortic valve disease. Curr Opin Lipidol 2004; 15:447-451.
49. Tziomalos K, Athyros VG, Karagiannis A, et al. Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention? Expert Opin Ther Targets 2008; 12:809-820.
50. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin- converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110:1291-1295.
51. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipidlowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389-2397.
52. Dichtl W, Alber HF, Feuchtner GM, et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 2008; 102:743-748.
53. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49:554-561.
54. Chan KL, Teo K, Dumesnil JG, et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306-314.
55. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-1356.
56. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359:1357-1366.
57. Wierzbicki AS. Muddy waters: more stormy SEAS for ezetimibe. Int J Clin Pract 2008; 62:1470-1473.
58. Williams CD. Not so choppy SEAS. J Clin Lipidol 2009; 3:11-13.
59. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261.
60. Investigators Gissi-HF, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 2008; 372:1231-1239.
61. Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008; 102:738-742.
62. Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther 2008; 6:385-390.
63. Cawley PJ, Otto CM. Prevention of calcific aortic valve stenosis-fact or fiction? Ann Med 2009; 41:100-108.
64. Drolet MC, Couet J, Arsenault M. Development of aortic valve sclerosis or stenosis in rabbits: role of cholesterol and calcium. J Heart Valve Dis 2008; 17:381-387.
65. Linhartova K, Veselka J, Sterbakova G, et al. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 2008; 72:245-250.
66. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21:817-824.
67. Goldstein RE. Bone modifiers and the quest to slow progression of aortic stenosis. Am J Cardiol 2009; 104:125-127.
68. Antonini-Canterin F, Leiballi E, Enache R, et al. Hydroxymethylglutaryl coenzyme- a reductase inhibitors delay the progression of rheumatic aortic valve stenosis a long-term echocardiographic study. J Am Coll Cardiol 2009; 53:1874-1879.